Objectives-To assess the acceptability of screening newborn boys for Duchenne muscular dystrophy.
Introduction
Screening of newborns for Duchenne muscular dystrophy by measurement of blood spot creatine kinase activity has been technically possible since a suitable assay was devised in the mid 1970s. ' Since then it has been offered on a limited basis in Germany2 and as a routine service in Lyons, France,3 and Antwerp, Belgium. There boys-Do you want it?" printed on blue paper. Midwifery staff are asked to give this to the mother sufficiently ahead of her discharge from hospital so that she can ask midwifery or paediatric staff any questions which might occur to her or her partner. When the community midwife calls at home on day 6 or 7 to take the heel prick blood sample for the usual screening tests she asks whether or not they want their son tested for Duchenne muscular dystrophy and marks the screening card accordingly.
Our protocol (available on request from the authors) for the follow up of a positive test result was govemed by three main considerations. Firstly, we are offering a family the diagnosis of a lethal untreatable disorder in an apparently healthy baby; secondly, the protocol was designed so that we could modify practice in the light of experience; and, thirdly, families should have choice at every stage from the initial screening test to a confirmed diagnosis. Clearly this is different from the normal practice in routine neonatal screening. To help with consistency of approach paediatricians in each of the nine health districts in Wales were asked to choose one or more of their number to be nominated for this project.
After a positive test result the family practitioner and health visitor are contacted when the baby is about six weeks old to develop a social profile of the family and decide how best to approach them to offer a venous blood test to confirm or refute the screening test. Before the family are contacted an appointment is arranged with the nominated paediatrician so that they can see the family within a day of their being approached by the primary health care team. At this meeting the paediatrician ensures that the family are aware of the screening programme and the options that are open to them. Ifthey agree a venous blood sample is taken and another appointment arranged within 24 hours to give the result so that the period of uncertainty and anxiety is minimised. After the result of the venous creatine kinase test has been given and explained families are invited to take part in the social evaluation of the screening programme. Should the screening test result be confirmed the family are offered genetic counselling and the opportunity to further the diagnostic process, initially by molecular genetic mutation analysis and subsequently by muscle biopsy and dystrophin analysis.
Creatine kinase activity is measured semiquantita- tively, fluorimetrically by a semiautomated version of that previously described.9 Though screening programmes for Duchenne muscular dystrophy have detected cases of Becker muscular dystrophy,3" whether all or any cases will be detected in this programme is not known. Until the results of long term follow up are available the ability of our creatine kinase assay to detect Becker cases remains uncertain.
Results and discussion
The overall figures for the first two years are given in table I. There have been a total of 16 positive test results, nine of which were confirmed on a subsequent venous sample, giving an incidence of 1:3802 male births. The creatine kinase increase in all nine infants has been shown to be due to the muscle isoenzyme. TRANSIENT CASES Though our screening method is semiquantitative, the seven unconfirmed cases did have creatine kinase values lower than those which were subsequently confirmed as increased on a later venous sample. Interestingly, five of these infants had some unusual perinatal features. One had been given intramuscular ampicillin for a septic cord; one had had a traumatic caesarean birth; one had had a difficult birth with vacuum extraction and he also had a ventricular septal defect; one had a heart murmur; and one had been premature and in a special care unit with hypotonia and jaundice. There is no evidence from any of the screening programmes to suggest that a transient elevation of creatine kinase activity in a neonate may lead to developing a muscular dystrophy in later life.
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. This reduces reporting time to a few days.
Muscle biopsies-Though all nine families opted for DNA analysis only five then chose to follow up with muscle biopsy and dystrophin analysis. This confirmed Duchenne muscular dystrophy in each case (table II) . In family 5 the mother's brother had previously been confirmed by muscle biopsy and so a biopsy on the infant was thought unnecessary. In spite of increasing knowledge about the gene, at the present time the only way to distinguish between Duchenne muscular dystrophy and the more benign allelic Becker muscular dystrophy is by muscle biopsy and dystrophin analysis. Though the incidence of Becker is only one tenth that of Duchenne muscular dystrophy, the three families who refused a biopsy did so on the grounds that while they accepted their son had a muscular dystrophy they preferred to live in the hope that it might be Becker and so chose not to complete the diagnostic process.
Familial cases-In two cases the screening programme identified two affected boys in a sibship before the elder boy had been diagnosed (table II) . When family 1 was detected the elder brother was under orthopaedic management for his abnormal gait but Duchenne muscular dystrophy had not been suspected. Seven mothers seem to be carriers based on their serum creatine kinase values. The mother in family 5 had a brother with Duchenne muscular dystrophy.
Genetic counselling was sought by all nine families, but it is still too soon to comment on their reproductive choices. Prenatal diagnosis, however, has been performed on the fetus of the aunt of one boy, and genetic counselling has been requested by several other members of the extended families.
Experience of the families-It would be neither feasible nor desirable to intrude upon these families at frequent intervals to monitor their response to the emergent diagnosis of Duchenne muscular dystrophy. We This family was the second detected and our practice has since been modified to make a disclosure no sooner than 6 weeks. Interestingly, this family lives in the area that is our poorest responder to the monthly listings of infants where parental choice was not stated on the screening sample (fig 2, area 27 ). The refusal rate in this area is now the highest in Wales and increased dramatically after the disclosure (fig 3) . Probably, in a close-knit community the negative response of this family has influenced the uptake of the test. Our concem is not the actual refusal rate but to ensure that families have choice on the basis of informed consent.
As part of the study of the emotional response of families to the early diagnosis of Duchenne muscular dystrophy we are also interviewing those families whose boys have undergone the later traditional diagnosis. This will allow us to compare the experiences of both groups. Implications for community education-From the outset, we have devoted a lot of effort to providing a continuing educational programme for health professionals. The importance of this cannot be overemphasised. The response from midwives, health visitors, and paediatricians to the education programme has generally been positive and has helped in the practical implementation of the test. It has also enabled the health professionals to give us feedback on the screening from their perspective.
Conclusion
When screening began we agreed to discontinue it at the end of the first year if there were a number of traumatised families. This has not been the case; in fact most families have been pleased to know the diagnosis so early. This permits future informed reproductive planning, avoids diagnostic complications and delays, and allows planning of care for the affected boy. We are confident that the programme -should continue to permit a full evaluation of the issues raised by screening newbom males for Duchenne muscular dystrophy and hope to extend its duration so that the perspectives of the families may be assessed as the boys develop symptoms and signs of muscular weakness.
We also believe that this project will serve as a model for the evaluation of other community genetic interventions, with its emphasis on offering optional tests based on informed consent and the education of primary health care teams. 
